Remarkable Pathologic Change in Advanced Prostate Cancer Patient Using Dendritic Cell–Cytokine-Induced Killer Combined Therapy: A Case Report

Xu, Peng; Li, Peng Ju; Guo, Kai; He, Yanjie; Ma, Chao; Zhang, Yiming; Ge, Yukun; Xu, Aiming; Zheng, Shaojiang; Li, Yuhua; Liu, Chunxiao; Huang, Peng

doi:10.1016/j.clgc.2015.04.006

Cited by 3 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Till now, it was the most mature checkpoint blockade. Recently, immune-based combination therapy of prostate cancer is being developed in full swing by preclinical and clinical studies [18, 19]. It is extremely important to examine the safety, efficacy, and side effects of combination therapy by analyzing the immune status.…”

Section: Discussionmentioning

confidence: 99%

Real-time monitoring of tumor progression and drug responses in a preclinical mouse model of prostate cancer

Guo

et al. 2016

Oncotarget

Self Cite

View full text Add to dashboard Cite

Monitoring disease progression through imaging is playing an increasingly important role in the treatment of prostate cancer. Here, we report that primary mouse prostate cancer cell lines stably expressing luciferase and tumor biomarkers can be monitored through bioluminescence imaging along with assays of serum biomarkers and immune function. Tumorigenesis in immunocompetent C57BL/6 mice can be monitored in by collecting samples from the dorsal flank, dorsolateral prostate, and tail vein to obtain real-time subcutaneous, orthotopic, and metastasis indicators, respectively. We used this technique to confirm the therapeutic effect of immune checkpoint blockade. Our findings suggest the presented indicators are ideally suited for real-time tracking of drug responses, tumor progression and immune function.

show abstract

Section: Discussionmentioning

confidence: 99%

Real-time monitoring of tumor progression and drug responses in a preclinical mouse model of prostate cancer

Guo

et al. 2016

Oncotarget

Self Cite

View full text Add to dashboard Cite

show abstract

“…DC therapies have been used in both preclinical and clinical trials for various cancers, such as prostate cancer, 12 , 13 multiple myeloma, 14 , 15 renal cell carcinoma, 16 , 17 pancreatic cancer, 18 , 19 leukemia, 20 melanoma, 21 colorectal cancer, 22 , 23 glioma, 24 , 25 and BC. 26 – 28 In almost all cases, DC vaccination was demonstrated to be a safe and effective method for treating metastatic patients.…”

Section: Introductionmentioning

confidence: 99%

Targeting breast cancer stem cells by dendritic cell vaccination in humanized mice with breast tumor: preliminary results

Pham

et al. 2016

OTT

View full text Add to dashboard Cite

BackgroundBreast cancer (BC) is one of the leading cancers in women. Recent progress has enabled BC to be cured with high efficiency. However, late detection or metastatic disease often renders the disease untreatable. Additionally, relapse is the main cause of death in BC patients. Breast cancer stem cells (BCSCs) are considered to cause the development of BC and are thought to be responsible for metastasis and relapse. This study aimed to target BCSCs using dendritic cells (DCs) to treat tumor-bearing humanized mice models.Materials and methodsNOD/SCID mice were used to produce the humanized mice by transplantation of human hematopoietic stem cells. Human BCSCs were injected into the mammary fat pad to produce BC humanized mice. Both hematopoietic stem cells and DCs were isolated from the human umbilical cord blood, and immature DCs were produced from cultured mononuclear cells. DCs were matured by BCSC-derived antigen incubation for 48 hours. Mature DCs were vaccinated to BC humanized mice with a dose of 106 cells/mice, and the survival percentage was monitored in both treated and untreated groups.ResultsThe results showed that DC vaccination could target BCSCs and reduce the tumor size and prolong survival.ConclusionThese results suggested that targeting BCSCs with DCs is a promising therapy for BC.

show abstract

The Therapeutic Potential of Cytokine-Induced Killer in Patients with Cancer

Zhong,

Zhang,

et al. 2024

Journal of Interferon & Cytokine Research

View full text Add to dashboard Cite

Remarkable Pathologic Change in Advanced Prostate Cancer Patient Using Dendritic Cell–Cytokine-Induced Killer Combined Therapy: A Case Report

Cited by 3 publications

References 25 publications

Real-time monitoring of tumor progression and drug responses in a preclinical mouse model of prostate cancer

Real-time monitoring of tumor progression and drug responses in a preclinical mouse model of prostate cancer

Targeting breast cancer stem cells by dendritic cell vaccination in humanized mice with breast tumor: preliminary results

The Therapeutic Potential of Cytokine-Induced Killer in Patients with Cancer

Contact Info

Product

Resources

About